


## REVIEW

# Expanding role of PI5P4Ks in cancer: A promising druggable target

Gurpreet K. Arora, Lavinia Palamiuc and Brooke M. Emerling 

Cell and Molecular Biology of Cancer Program, Sanford Burnham Prebys, La Jolla, CA, USA

## \*Correspondence

B. M. Emerling, Cell and Molecular Biology of Cancer Program, Sanford Burnham Prebys, La Jolla, CA 92037, USA  
 Tel: +1 858-646-3100  
 E-mail: bemerling@sbpdiscovery.org

(Received 1 October 2021, revised 4 November 2021, accepted 15 November 2021, available online 7 December 2021)

doi:10.1002/1873-3468.14237

Edited by Lukas Alfons Huber

Cancer cells are challenged by a myriad of microenvironmental stresses, and it is their ability to efficiently adapt to the constantly changing nutrient, energy, oxidative, and/or immune landscape that allows them to survive and proliferate. Such adaptations, however, result in distinct vulnerabilities that are attractive therapeutic targets. Phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks) are a family of druggable stress-regulated phosphoinositide kinases that become conditionally essential as a metabolic adaptation, paving the way to targeting cancer cell dependencies. Further, PI5P4Ks have a synthetic lethal interaction with the tumor suppressor p53, the loss of which is one of the most prevalent genetic drivers of malignant transformation. PI5P4K's emergence as a crucial axis in the expanding landscape of phosphoinositide signaling in cancer has already stimulated the development of specific inhibitors. Thus, a better understanding of the biology of the PI5P4Ks will allow for targeted and effective therapeutic interventions. Here, we attempt to summarize the mounting roles of the PI5P4Ks in cancer, including evidence that targeting them is a therapeutic vulnerability and promising next-in-line treatment for multiple cancer subtypes.

**Keywords:** cancer; cellular energetics; lipid kinase; metabolic dependency; p53; phosphoinositides; PI-4,5-P<sub>2</sub>; PI-5-P; PI5P4K inhibitors; PI5P4Ks (PIP4K)

Phosphoinositides comprise only a small group of phospholipids. However, they are fundamental signaling molecules that are involved in numerous essential cellular processes such as membrane trafficking, cytoskeletal organization, cell survival, and proliferation [1]. Understandably, dysregulation of phosphoinositide metabolism is associated with prevalent conditions, such as obesity, type 2 diabetes, neurodegenerative disorders, and cancer [2–4]. Recently, they

have also drawn increased attention due to the ability of infectious agents to utilize phosphoinositides for their trafficking, replication, and assembly [5]. Phosphoinositides are derived by the phosphorylation of the third, fourth, and fifth positions of the inositol headgroup of phosphatidylinositol (PI), resulting in the generation of seven distinct phosphoinositide derivatives [4]. In eukaryotic cells, these seven phosphoinositide species are interconverted into each other

## Abbreviations

ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; ERBB2, Erb-B2 receptor tyrosine kinase 2; GBM, glioblastoma; GEM, genetically engineered model; GTEx, genotype-tissue expression; MEF, mouse embryonic fibroblast; PI, phosphatidylinositol; PI-3,4,5-P<sub>3</sub>, phosphatidylinositol-3,4,5-triphosphate; PI3K, phosphoinositide 3-kinase; PI-4,5-P<sub>2</sub>, phosphatidylinositol 4,5-bisphosphate; PI-4-P, phosphatidylinositol 4-phosphate; PI4P5K, phosphatidylinositol 4-phosphate 5-kinase; PI-5-P, phosphatidylinositol 5-phosphate; PI5P4K, phosphatidylinositol 5-phosphate 4-kinase; Pin1, peptidyl-prolyl cis-trans isomerase NIMA-interacting 1; PTEN, phosphatase and tensin homolog; SARC, sarcoma; SNPs, single nucleotide polymorphisms; TCGA, The Cancer Genome Atlas; TNBC, triple-negative breast cancer; T<sub>regs</sub>, regulatory T cells.

through the precise and spatially regulated activity of phosphoinositide kinases and phosphatases [4]. In fact, the importance of maintaining a tight balance between the activities of the various phosphoinositide-metabolizing enzymes, to control the cellular phosphoinositide pools, is underscored by the diseases, including cancers, that arise from dysregulation. One of the most established phosphoinositide kinases linked to cancer is phosphoinositide 3-kinase (PI3K). PI3K phosphorylates phosphatidylinositol 4,5-bisphosphate (PI-4,5-P<sub>2</sub>) to generate phosphatidylinositol-3,4,5-triphosphate (PI-3,4,5-P<sub>3</sub>) leading to the subsequent activation of Akt and its downstream signaling cascades, which has set the stage for phosphoinositide signaling in cancer research [6]. On the other hand, the tumor suppressor protein, phosphatase, and tensin homolog (PTEN) acts as a major inhibitory regulator of the PI3K-Akt oncogenic pathway, by dephosphorylating PI-3,4,5-P<sub>3</sub> to PI-4,5-P<sub>2</sub>, and is thus a common target of inactivation in cancer [7]. Notably PI3K is also one of the most frequently mutated genes in cancer, which has led to the emergence of inhibitors targeting PI3K entering the clinic for cancer therapy. Interestingly, the PI3K product PI-3,4,5-P<sub>3</sub> is practically nonexistent from quiescent cells but is rapidly stimulated by extracellular factors, whereas PI-4,5-P<sub>2</sub> is abundant in cells [8]. PI-4,5-P<sub>2</sub> is an established regulator of multiple cellular processes, such as being a precursor to generate the second messengers diacylglycerol and inositol-1,4,5-trisphosphate, signaling, vesicular trafficking, membrane dynamics, and gene expression, and importantly, there are increasing reports that now connect PI-4,5-P<sub>2</sub> signaling to diseases, such as cancer, including leukemia, melanoma, and breast cancer [4,9]. Yet, there is still a great deal to learn about how PI-4,5-P<sub>2</sub> is regulated and in particular about the enzymes that produce PI-4,5-P<sub>2</sub>. Besides being generated by the dephosphorylation of PI-3,4,5-P<sub>3</sub>, there are other pathways for PI-4,5-P<sub>2</sub> generation, involving the activity of two divergent families of lipid kinases, which generate the lipid through phosphorylation of monophosphoinositides.

These phosphoinositide kinases that generate PI-4,5-P<sub>2</sub> were first purified from erythrocytes in the late 1980s and were separated into two groups, Type I and Type II kinases, based on their biochemical and immunogenic phenotypes [10,11]. However, in 1997 the Cantley lab made the unexpected finding that the Type II kinases actually made PI-4,5-P<sub>2</sub> by phosphorylating the 4-position of PI 5-phosphate (PI-5-P), a contaminant that was present in the commercial PI 4-phosphate (PI-4-P) [12]. Not only did this discovery show for the first time that PI-4,5-P<sub>2</sub> could be


generated from two independent pathways, but most importantly it revealed PI-5-P, which was not known to exist. Further, these groundbreaking observations defined the two pathways that generate PI-4,5-P<sub>2</sub> in mammalian cells, as the Type I canonical pathway in which the PI 4-phosphate 5-kinases (PI4P5Ks) phosphorylate the 5-position of PI-4-P to generate PI-4,5-P<sub>2</sub>, and the noncanonical pathway where the PI 5-phosphate 4-kinases (PI5P4Ks) phosphorylate the 4-position of PI-5-P to make PI-4,5-P<sub>2</sub>. Despite the fact Type I and Type II kinases generate the same lipid product, over the years it is becoming increasingly apparent that these distinct families have diverse biological and metabolic functions. Further, the cellular location of where these enzyme families produce PI-4,5-P<sub>2</sub> is crucial. Whereas the Type I canonical pathway generates PI-4,5-P<sub>2</sub> predominantly at the plasma membrane, the Type II noncanonical produced PI-4,5-P<sub>2</sub> occurs largely on intracellular membranes, such as lysosomes [13] and peroxisomes [14]. In this review, we will focus on the noncanonical PI5P4Ks, which are emerging into the limelight as cancer targets, especially for cancers with metabolic liabilities.

## The PI5P4K family

In mammals, the PI5P4K family consists of three isoforms ( $\alpha$ ,  $\beta$ , and  $\gamma$ ), and the genes encoding the PI5P4Ks are called *PIP4K2A*, *PIP4K2B*, and *PIP4K2C* [15–18]. The importance of this alternative pathway to generate PI-4,5-P<sub>2</sub> is emphasized by the fact that the PI5P4K family is conserved back to *Drosophila* and *Caenorhabditis elegans*, each having a single catalytically active PI5P4K that is essential for survival during metabolic stress [13,18–20].

At the protein level, the PI5P4K $\alpha$  and  $\beta$  isoforms are 83% identical and PI5P4K $\gamma$  is approximately 60% identical to PI5P4K $\alpha$  and  $\beta$  [21]. The distinct features of their structural organization are a dimerization domain and the kinase domain, which includes the catalytic activity residues, substrate binding site, and a specificity loop that together determine the preference for PI-5-P binding (Fig. 1) [22,23]. Of the three isoforms, PI5P4K $\alpha$  is the most catalytically active, displaying significantly more activity compared to PI5P4K $\beta$ , whereas PI5P4K $\gamma$  has very little inherent activity [18,24]. It is noteworthy that these are dimeric enzymes and thus are capable of forming heterodimers with each other, which has been speculated to be fundamental for their functional relevance at specific cellular locations, particularly for the less active isoforms [25,26].

**Fig. 1.** Domain organization of PI5P4Ks. The schematic representation illustrates the similarity between the three human isoforms (UniProt identifier: [P48426](#), [P78356](#), and [Q8TBX8](#)) and depicts the dimerization and kinase domain. It also includes the phosphorylation sites on PI5P4K $\beta$  at Ser<sup>326</sup> for p38 MAP kinase or at Thr<sup>322</sup> by an unidentified kinase and the phosphorylation site on PI5P4K $\gamma$  at Ser<sup>324</sup> and Ser<sup>328</sup> for mTORC1.



All isoforms are ubiquitously expressed. As for the particular subcellular locations and functions of the PI5P4K isoforms, there still remain gaps in our knowledge. However, to date what definitely can be said is that the individual isoforms are indeed present at distinct cellular locations, thus providing a rationalization of why higher organisms evolved to have three isoforms [27]. Endogenous PI5P4K $\alpha$  has been shown to be in the cytosol and recent overexpression, and genetic studies have demonstrated that this isoform can localize to autophagosomes, lysosomes, and peroxisomes [13,14,28]. PI5P4K $\beta$  predominantly localizes to the nucleus, yet overexpression experiments have indicated that both the PI5P4K $\beta$  and PI5P4K $\gamma$  isoforms are present at autophagosomes [26,28]. Further, PI5P4K $\gamma$  has been shown to reside within the endomembrane compartment and partially localize with the Golgi [29].

Upstream regulation of the lipid kinases has remained unexplored. The regulation is most likely driven by cellular requirements for the substrate, PI-5-P, or for the product, PI-4,5-P<sub>2</sub>. Like PI-3,4,5-P<sub>3</sub>, PI-5-P, the last phosphoinositide to be discovered, is minimal in abundance; however, levels are increased upon cellular stress [30–32]. There is some evidence that the increased levels of PI-5-P, under stress, are achieved by inhibitory phosphorylation of PI5P4K $\beta$  by MAP kinase p38 at Ser<sup>326</sup> [30] (Fig. 1). Further, phosphorylation of the kinases at Ser<sup>326</sup> by p38 or at Thr<sup>322</sup> by an unidentified kinase (Fig. 1) was found to be responsible for the interaction of both PI5P4K $\alpha$  and PI5P4K $\beta$  with Pin1, allowing for inhibitory regulation of the lipid kinase activity [33] to regulate PI-5-P pools. Pin 1, or peptidyl-prolyl cis/trans isomerase (PPIase), is known to regulate the function of multiple proteins due to its ability to isomerize the serine/threonine-proline motif [34]. To expand on phosphorylation-dependent regulation of PI5P4Ks,


there has also been evidence for mTORC1-dependent phosphorylation of PI5P4K $\gamma$  at Ser<sup>324</sup> and Ser<sup>328</sup> [35] (Fig. 1) for maintaining optimal activation of mTORC1 through a feedback loop. The amount of PI-4,5-P<sub>2</sub> synthesized from PI-5-P is minor compared to the amount generated by the canonical PI4P5Ks, as their lipid substrate PI-4-P is one of the most abundant phosphoinositide. Due to these discrepancies, it was assumed that the PI5P4Ks evolved to solely control PI-5-P levels under stress conditions instead of producing PI-4,5-P<sub>2</sub> [30,33,36]. However, recent studies have suggested that the specialized PI-4,5-P<sub>2</sub> pools generated by the PI5P4Ks by phosphorylating PI-5-P on intracellular membranes in fact are critical for processes, such as peroxisome function, cholesterol trafficking, and tumorigenesis [13,14,37]. Furthermore, these findings highlight the importance of PI5P4K activity and the increasing relevance for these enzymes in a variety of pathological processes, including cancer.

## PI5P4Ks in cancer

In this section, we will focus on recent advances made in elucidating the roles of all the PI5P4K isoforms in the pathogenesis of multiple cancer types (Table 1). PI5P4Ks are not usually mutated in cancers but have been shown to have altered expression in most cancers. Different cancers are characterized with dissimilar cellular and microenvironmental requirements. In this context, changes in expression of PI5P4Ks would be consistent with their role in predominantly acting as an interface between the various intracellular organelles and their environment, making them sensitive to alterations in the demands of a tumor. As an initial glimpse into the expression of *PIP4K2A*, *PIP4K2B*, and *PIP4K2C* in different cancers, Fig. 2 illustrates comparative expression data of normal vs tumor

**Table 1.** PI5P4Ks in cancer. Summary of the multiple cancer types in which PI5P4Ks have been implicated. Alongside with each cancer type is the information about the associated isoform and a brief description of the evidence, function, and putative mechanism in cancer.

Cancer type	Implicated isoform	Evidence/potential mechanism
Breast	PI5P4K $\alpha$ , PI5P4K $\beta$	<ul style="list-style-type: none"> <li>High expression of both PI5P4K<math>\alpha</math>, PI5P4K<math>\beta</math> in tumor samples and co-occurrence with p53 mutations [15,39]</li> <li>Dual-kinase inhibition in cell lines results in decreased survival and impairs tumor growth in xenograft model [15]</li> <li>Impaired ROS homeostasis and mitochondrial functioning [15,37]</li> </ul>
AML	PI5P4K $\alpha$ , PI5P4K $\gamma$	<ul style="list-style-type: none"> <li>High expression of both PI5P4K<math>\alpha</math>, PI5P4K<math>\gamma</math> isoforms correlates with high-risk patient groups [43]</li> <li>Knockdown of PI5P4K<math>\alpha</math> in AML cell lines decreases survival and protects from leukemia in xenograft studies [47]</li> <li>mTOR-dependent accumulation of CDKN1 and apoptosis [47]</li> </ul>
ALL	PI5P4K $\alpha$	<ul style="list-style-type: none"> <li>SNPs in the Pip4k2a locus have been associated with genetic predisposition to ALL [48,50]</li> </ul>
SARC	PI5P4K $\alpha$ , PI5P4K $\beta$	<ul style="list-style-type: none"> <li>High expression of PI5P4K<math>\alpha</math> correlates with high-grade SARC [37]</li> <li>Dual-kinase inhibition decreases cell growth and survival <i>in vitro</i>, impairs tumor initiation and maintenance <i>in vivo</i> [37]</li> <li>Altered mitochondria function due to impaired peroxisomal beta oxidation [37]</li> </ul>
GBM	PI5P4K $\alpha$	<ul style="list-style-type: none"> <li>Low PI5P4K<math>\alpha</math> expression in tumor sections compared to matched normal sections in TMA study [53]</li> <li>Impaired cell proliferation and tumor growth with overexpression of PI5P4K<math>\alpha</math> [53]</li> <li>Negative regulation of PI3K signaling in PTEN deficiency background [53]</li> </ul>

**Fig. 2.** Comparative overview of PI5P4K isoform expression in multiple cancers. The heat map is organized based on the difference in median expression between the tumor samples (TCGA datasets) and the corresponding normal tissue samples (from GTEx and TCGA datasets [38]), and the cancer types are ranked based on PIP4K2A expression, going from cancers in which it is most upregulated to the ones it is most downregulated. Cancers highlighted in this review are LAML, SARC, BRCA, and GBM.

samples from tools that utilize publicly available datasets in the genotype-tissue expression (GTEx) portal and The Cancer Genome Atlas (TCGA) [38]. The

three isoforms are upregulated in some cancers and downregulated in others. This can be potentially explained by the fact that different cancers are

characterized by unique molecular, genetic, metabolic, and immune landscape, which results in personalized requirements and thus in distinct rewiring of gene expression profiles. It is interesting to note that the  $\alpha$  and  $\beta$  isoforms have a similar expression profile in multiple cancer types and  $\gamma$  has its own distinct profile, suggesting that they might exhibit different functions in cancers. Given the expression analysis tool does not carefully take into consideration the complexity and heterogeneity of tumors, this information should be considered as an initial guiding platform. In future, not only are additional datasets required, but there is a need for them to be segregated and profiled more appropriately so that valuable information can be obtained through such comparative studies. For PI5P4Ks, in fact, there is evidence suggesting they act both as oncogenes as well as tumor suppressors, and these studies are mostly consistent with the expression profile obtained through the public datasets (Fig. 2). Nonetheless, most studies favor oncogenic roles for the PI5P4Ks, and we will discuss some of these studies in detail below.

### Breast cancer

Breast cancer is a predominant cause of cancer-related mortality among women worldwide. It is a heterogeneous disease that has been classified into immunohistochemistry-based subtypes based on the expression of estrogen or progesterone receptors and human epidermal growth factor 2 [Erb-B2 receptor tyrosine kinase 2 (ERBB2); formerly HER2] amplification. The first study to implicate PI5P4Ks in cancer and for setting the stage for oncological research was in breast cancer [15]. Elevated expression of both PI5P4K $\alpha$  and PI5P4K $\beta$  was observed in breast tumors compared with normal breast tissue (Table 1) [15]. The gene encoding *PIP4K2B*, which is located at 17q21.2, lies in close proximity to the proto-oncogene *ERBB2* gene, thus often resulting in co-amplification [15,39,40]. However, high expression of *PIP4K2B* was also observed to be independent of *ERBB2* expression levels, raising the possibility of potential benefit of PI5P4K $\beta$  inhibitors to patients that display resistance to HER2-targeted therapy [15].

Remarkably, the same study elucidated a striking co-occurrence between high *PIP4K2A* expression as well as *PIP4K2B* amplification with *TP53* mutation/deletion. This led to the identification of a synthetic lethal interaction between PI5P4Ks and *TP53*, an important breakthrough in the search for vulnerabilities to target cancers with p53 loss/mutation. p53 is a tumor suppressor, and thus, its inactivation is a central

genetic driver of malignancies, rendering it difficult to target with drugs. Emerling *et al.* further showed that the unique PI5P4Ks create synthetic lethality when deleted or inhibited in ERBB2 amplified *TP53*-mutant breast cancer cells, but not in breast cancer cells or normal mammary epithelial cells that express wild-type *TP53*. This was attributed to increased oxidative stress and suppressed glucose metabolism. Furthermore, the kinase depleted *TP53*-mutant breast cancer cell line failed to form xenograft tumors in nude mice [15] (Table 2). Importantly, the study went on to utilize the *Trp53*<sup>-/-</sup> genetically engineered model (GEM), which forms spontaneous tumors and has a survival span of about 4–6 months. Loss of PI5P4Ks (*Pip4k2a*<sup>-/-</sup>, *Pip4k2b*<sup>+/-</sup>, *Trp53*<sup>-/-</sup>) in this well-established mouse tumor model resulted in a significant increase in tumor-free survival (Table 2) and in embryonic lethality upon loss of *Trp53* and *Pipk2b* [15] (Table 2). Not much progress has been made in the translation of synthetic lethal therapies to the clinic yet, despite the extensive research efforts in this promising nature of cancer treatment. PARP inhibitors, which target the inhibition of DNA repair pathways, have been the only FDA approved drug based on the synthetic lethal approach to target breast invasive carcinoma (BRCA) 1/2-mutated tumors [41]. Given that tumors are mostly fueled by multiple mutations, identification of synthetic lethal partners for different drivers can be utilized to develop powerful combination therapies to concurrently target multiple adaptations that are generated by these genomic alterations. This could also help to overcome the commonly faced issues with drug resistance in clinical practice. Why there is a synthetic lethal interaction between p53 and PI5P4Ks is briefly discussed in the next section but is definitely a question that warrants future investigation.

In another recent study by us, the role of PI5P4Ks in breast cancer was expanded to the triple-negative breast cancer subtype (TNBC), which uncovered a role of PI5P4Ks in cellular energetics. Downregulation of both the  $\alpha$  and  $\beta$  isoforms of PI5P4Ks suppressed the proliferative capacity of multiple TNBC cell lines and exposure to metabolic stress dramatically diminished the cellular viability [37], expanding the critical role of PI5P4Ks in multiple breast cancer subtypes. It will be imperative to investigate a larger panel of TNBC models, given the poor prognosis and limited therapeutic success for this subtype. Also, current studies suggest implication of both the  $\alpha$  and  $\beta$  isoforms, making it an important consideration for drug development. Further, in a recent comprehensive analysis of the secretome of breast cancer, the tumor interstitial fluid (TIF) proteome was characterized and identified PI5P4K $\beta$  as



**Table 2.** *In vivo* targeting of PI5P4Ks. Summary of the *in vivo* evidence of targeting PI5P4Ks in mouse models. The top half of the table comprises the phenotypes of the genetic models of kinase deletion, including germline deletions and the GEM model of SARC. The bottom half includes the outcomes of the multiple tumor implantation models in which PI5P4Ks were manipulated.

Genetic mouse models	Implicated isoform	Phenotype
<i>Pip4k2a</i> <sup>-/-</sup>	PI5P4K $\alpha$	Normal health and life span [15]
<i>Pip4k2b</i> <sup>-/-</sup>	PI5P4K $\beta$	Normal life span; retarded growth; insulin sensitivity [16]
<i>Pip4k2c</i> <sup>-/-</sup>	PI5P4K $\gamma$	Hyperinflammation; increased helper T cells and reduced T <sub>regs</sub> [17]
<i>Pip4k2b</i> <sup>-/-</sup> <i>Trp53</i> <sup>-/-</sup>	PI5P4K $\beta$	Embryonic lethal [15]
<i>Pip4k2a</i> <sup>-/-</sup> <i>Pip4k2b</i> <sup>+/-</sup> <i>Trp53</i> <sup>-/-</sup>	PI5P4K $\alpha$ , PI5P4K $\beta$	Increased tumor-free survival compared to <i>Trp53</i> <sup>-/-</sup> [15]
<i>Kras</i> <sup>LSL-G12D/+</sup> <i>Trp53</i> <sup>fix/fix</sup> <i>Pip4k2a</i> <sup>fix/fix</sup> <i>Pip4k2b</i> <sup>-/-</sup>	PI5P4K $\alpha$ , PI5P4K $\beta$	Restricted tumor formation and increased survival compared to <i>Kras</i> <sup>LSL-G12D/+</sup> <i>Trp53</i> <sup>fix/fix</sup> [37]
Tumor implantation models	Implicated isoform	Phenotype
Xenograft		
BT474 Breast cancer p53 mutant cell line	PI5P4K $\alpha$ , PI5P4K $\beta$	Impaired tumor growth with kinase knockdown [15]
THP1 AML cell line	PI5P4K $\alpha$	No evidence of leukemic engraftment with kinase knockdown [47]
SV40 transformed MEF	PI5P4K $\beta$	Decreased tumor growth with GTP-insensitive <i>Pip4k2b</i> [61]
LN428 GBM cell line	PI5P4K $\alpha$	Increased tumor growth with kinase knockdown [53]
Orthotopic		
GBM cell line	PI5P4K $\alpha$	Decreased tumor growth with kinase overexpression [53]
KPS-142 SARC cell line	PI5P4K $\alpha$ , PI5P4K $\beta$	Decreased tumor growth with kinase knockdown [37]

one of the 10 proteins that can be used as a reliable biomarker to stratify the breast cancer tumor subtypes, all of which were also analyzed by immunohistochemistry (IHC) on matched tumor tissue samples [42]. In summary, all of the above data points to clinical relevance of PI5P4Ks in breast cancer and to a promising outcome with the targeting of PI5P4Ks in a broad population of breast cancer patients, particularly including those that harbor altered *TP53* status.

### Acute leukemias

Acute leukemias are common malignant disorders worldwide and are classified into myeloid or lymphoid according to the predominant lineage of the hematopoietic cell involved. Acute myeloid leukemia (AML) is prevalent mostly in adults, whereas acute lymphocytic leukemia (ALL) is one of the most common pediatric cancers. PI5P4K $\alpha$  has been implicated in both of the acute leukemias in multiple studies [43–45] (Table 1). Phosphoinositide signaling plays an important role in hematological malignancies [46], and this motivated a study in which a knockdown-based screening of phosphoinositide signaling regulators was performed in AML cells, and interestingly, PI5P4K $\alpha$  was found to be required for survival and proliferation of the AML cells [47]. They further demonstrated that PI5P4K $\alpha$  was important for the proliferation potential of both human and mouse AML cells but not for normal hematopoietic stem and progenitor cells [47], indicating that the alpha isoform is essential under rewired signaling of cancer

cells. Reassuringly, alpha isoform-depleted AML cells did not result in leukemia in the tumor implantation study [47] (Table 2). *In vitro*, the phenotype was attributed to a mTOR-dependent increase in CDKN1A accumulation. High expression of not only PI5P4K $\alpha$  but also of PI5P4K $\gamma$  was found to be associated with unfavorable clinical outcomes for AML patients [43]. Genome-wide association studies have also identified several single nucleotide polymorphisms (SNPs) in the *PIP4K2A* locus that have been associated with a genetic predisposition in ALL [48–50]; however, the contribution of the SNPs to *PIP4K2A* expression or the functional involvement of PI5P4K $\alpha$  to the leukemogenesis of ALL is still unexplored. Nevertheless, targeting PI5P4Ks in acute leukemias could be a promising treatment either by itself or as a combination therapy [45].

### Glioblastoma

Glioblastoma (GBM) is the most prevalent and lethal malignant brain tumor with extremely low survival rate in the range of few months to < 3 years [51]. Loss of PTEN is observed in approximately 60% of GBM patients and is associated with poor prognosis and drug resistance. Given the antagonizing role of PTEN to the oncogenic PI3K–Akt signaling, loss of PTEN is associated with increased Akt activation in GBM. However, pharmacological inhibition of PI3K inhibitors has not been very successful in improving the outcome in GBM [52]. In a recent study in GBM, Shin *et al.* [53] performed an *in vivo* RNAi screen to

identify putative tumor suppressors and established PI5P4K $\alpha$  as a robust candidate. Interestingly, both *PIP4K2A* and *PTEN* are located on chromosome 10, and by analyzing the TCGA dataset for GBM, they found that a large majority of the patients exhibited genomic deletion of both, and this associated with poor survival outcomes. However, patients with high *PIP4K2A* expression demonstrated a significant survival advantage when compared with patients lacking *PIP4K2A* in *PTEN*-deleted GBM patients, highlighting the clinical relevance of PI5P4K $\alpha$  in GBM. Using both *in vitro* and *in vivo* approaches (Tables 1 and 2), they demonstrate that PI5P4K $\alpha$  attenuates cell proliferation and tumorigenesis in *PTEN*-deficient GBMs [53]. PI5P4K's role as a tumor suppressor in GBM is attributed to its ability to negatively regulate PI3K-Akt signaling by targeting the p85 adaptor subunit of class IA PI3Ks for proteasome-mediated degradation [53]. The group further elucidated that PI5P4K $\alpha$  regulates the stability of the PI3K complex independent of its kinase activity, broadening the scope of these lipid enzymes in cancer beyond the modulation of phosphoinositide cellular pools.

### Soft tissue sarcomas

Soft tissue sarcomas (SARCs) are a very heterogeneous group of malignancies and encompass more than 80 different subtypes. Current standard of care is limited to surgical resection and radio-chemotherapy for localized cases, and metastatic disease is usually treated with cytotoxic chemotherapy [54]. SARCs have been underexplored and thus also lack safe and effective therapeutic interventions. Intriguingly, lymphomas as well as soft tissue SARCs are the most frequently occurring tumor types in the *Trp53*<sup>-/-</sup> mouse cancer model, raising the possibility of PI5P4Ks involvement in SARCs. Indeed, inhibition of both PI5P4K $\alpha$  and PI5P4K $\beta$  in a panel of SARC cell lines resulted in a proliferation and survival disadvantage, similar to the TNBC panel of cells described above [37]. Using a tissue microarray representing 50 different soft tissue entities, spanning from benign tumors to highly aggressive, treatment-naïve SARCs, we showed strong correlation of high PI5P4K $\alpha$  expression with high-grade SARCs with no to low expression in benign/low grade SARCs, indicating that high expression of PI5P4Ks might be associated with poor prognosis [37]. Relevance of PI5P4Ks in SARC pathogenesis was further established using the preclinical *Kras*<sup>LSL-G12D/+</sup> *Trp53*<sup>flx/flx</sup> (KP) model [55] (Table 2), which successfully recapitulates the human disease. Using this model, it was demonstrated for the first time that PI5P4Ks control tumor

formation since genetic deletion of the kinases resulted in diminished tumor formation and increased survival [37]. Furthermore, the kinases were silenced in a cell line that was established from a KP tumor. Tumor implantation studies using these cells resulted in drastically diminished tumor growth supporting the essentiality of PI5P4Ks for tumor maintenance [37] (Tables 1 and 2). This comprehensive study offers a glimpse of hope for difficult to treat SARC subtypes and has expanded the cancer relevance of the PI5P4Ks. The functional requirement of PI5P4Ks in SARCs is discussed in further detail in the next section.

### What are the functional roles of the PI5P4Ks in cancer?

As from the above cancer studies, there is indeed growing evidence for functional requirement of PI5P4Ks in controlling tumorigenesis. In this section, we describe recent studies in various *in vitro* and *in vivo* models that can enable us to infer potential functional roles of PI5P4Ks that make them vital in cancer.

### Genetic models


Here, we will first discuss some of the genetic models of targeting the different isoforms of PI5P4Ks and their phenotypes (Table 2). Mice lacking the most catalytically active isoform, *Pip4k2a*<sup>-/-</sup>, have a normal lifespan and did not manifest any striking metabolic or developmental phenotypes; however, it will be interesting to see if challenged with metabolic or nutrient stresses how these mice would cope with such adversities. Mice with homozygous germline deletion of *Pip4k2b*, *Pip4k2b*<sup>-/-</sup>, were found to demonstrate increased insulin sensitivity, were growth retarded and protected from obesity when subjected to a high-fat diet [16]. Similarly, inactivation of the only PI5P4K isoform in *Drosophila*, *dPIP4K*<sup>29</sup>, also resulted in developmentally delayed animals possibly due to decreased mTOR signaling [20], and in modulation of insulin receptor signaling along with partial protection from the effects of exposure to high sugar diet [56]. Germline deletion of the least catalytically active isoform, *Pip4k2c* (*Pip4k2c*<sup>-/-</sup>), resulted in viable mice, but they exhibited a mTOR-dependent increase in inflammation with an increase in proinflammatory cytokines and T helper cells, as well as a decrease in regulatory T cells (T<sub>regs</sub>) [17]. Mice lacking both of the most catalytically active isoforms, *Pip4k2a*<sup>-/-</sup> *Pip4k2b*<sup>-/-</sup>, develop into normal embryos, but die within 10–12 h after birth resulting in perinatal lethality [15]. This is phenotypically similar to observations

in mice with impaired metabolic and nutrient signaling, including mTOR signaling, insulin/IGF signaling, and autophagy [13]. *In vivo* targeting of PI5P4Ks in the *Trp53*<sup>-/-</sup> and KP SARC models has revealed the importance of the kinases in both tumor initiation and maintenance [15,37]. It is not evident as to what functions of PI5P4Ks make them crucial for tumorigenesis in these *in vivo* models, yet the *in vitro* results from the same studies point toward crucial influence on cellular energetics. Performing metabolomic profiling in tumor models might provide the necessary insights into the pathways through which the lipid kinases provide an advantage to tumors. Moreover, it will be exciting to evaluate the consequences of targeting PI5P4Ks in more sophisticated preclinical mouse models, including breast, ovarian, and pancreatic cancer, all of which

have high mutational burden of *TP53*. Investigation of interactions with other genetic drivers of malignancy will be another exciting prospect that might allow teasing out the metabolic adaptations under which targeting the PI5P4Ks would have the most meaningful affect in tumor control. In summary, all of the *in vivo* mouse models to date point broadly toward functional engagement of PI5P4Ks in the regulation of cellular energetics as well as in immune modulation, both of which are crucial hallmarks of cancer (Fig. 3).

### Recent insights

Alteration in the activities of PI5P4Ks will vary the cellular pool of phosphoinositides, and such changes can govern the proliferative and invasive capacity of



**Fig. 3.** Multipronged effect of pharmacological targeting of PI5P4Ks in the fight against cancer. PI5P4Ks perform a central role in influencing multiple cancer hallmarks due to its dual role in cell-intrinsic pathways as well as in modulation of the immune environment. PI5P4Ks contribute to the classic hallmark of evading cell-death pathways since targeting them selectively decreases survival of cancer cells. PI5P4Ks potentially regulates specialized phosphoinositide pools in subcellular organelles and modulates the dynamic contacts between organelles, exerting a far-reaching impact on cellular energetics as demonstrated by disruption of autophagy, cholesterol trafficking, ROS homeostasis, and efficient peroxisomal-mitochondrial cross talk with the manipulation of the kinases. Several of the above-described functional implications arise as a result of alteration in signaling of mTOR, PI3K-Akt, and AMPK networks, all of which have been crucial clinical targets for cancer treatment modalities. PI5P4Ks extend their relevance in tumor biology beyond the boundaries of the cells and into the microenvironment by selectively affecting the activity of the T<sub>regs</sub>, allowing for the PI5P4K inhibitors to act as a combination of chemo- and immunotherapy.



cancer cells [57,58]. Mostly, due to the changes in these pools, PI5P4Ks have been demonstrated to play important roles in growth control [20,59], cellular energetics and metabolism [13,37,60], oxidative stress regulation [31,32], cholesterol trafficking [14], GTP sensing [61], and immune function [17,62]. Here, we will highlight some of the recent advancements in our understanding of the cellular functions of PI5P4Ks which would be relevant in the context of tumorigenesis (Fig. 3). We will not be discussing some of the studies that have been described in previous reviews [22,27,63,64].

### Metabolic dependencies

Cancer cells generate context dependent metabolic patterns to meet their excessive demands for membrane components and nutrients. Autophagy serves as one of the adaptive metabolic responses and provides access to metabolites to meet the demands of the highly proliferative cancer cells [65]. PI-5-P was revealed to be a regulator of autophagosome biogenesis and changes in its pool by silencing of the PI5P4Ks resulted in increased number of autophagosomes [28]. The role of PI5P4Ks in autophagy, under metabolic stress, has been further elucidated in the study by Lundquist and colleagues, which took advantage of multiple genetic models from worms to mice [13]. Inhibition of the  $\alpha$  and  $\beta$  isoforms of PI5P4K results in a striking accumulation of autophagic vesicles due to a defect in autophagosome-lysosome fusion (Fig. 3), leading to metabolic stress, which in turn suppresses mTORC1 signaling and upregulated the transcription factor EB regulated transcriptional program [13]. Notably, the autophagy defect in mouse embryonic fibroblasts (MEFs) was observed only when p53 was inhibited but not in MEFs with functional p53. p53 signaling has been implicated to be a prominent mediator of the autophagy pathway in tumors, and this study provides a functional interaction between p53 and PI5P4K. Whether this ability of PI5P4Ks to mediate autophagy applies to cancer cells, and whether dysregulation of autophagy can explain the synthetic lethal phenotype remains to be determined. Multiple pharmacological approaches are targeted toward disruption of autophagy either alone or in combination with other therapies but have not been so successful clinically, largely due to metabolic differences in cancers [66]. Therefore, targeting PI5P4Ks might potentially have better efficacy, at least in the p53 disrupted patient population.

Cholesterol is a crucial membrane component and is also important for generating metabolites that play

an integral role in supporting cancer progression. Reprogrammed cholesterol metabolism is driving the need to develop therapeutic targets to alter different aspects of cholesterol metabolism including synthesis, uptake, efflux, and trafficking [67]. PI5P4K $\alpha$  was shown to be important for intracellular cholesterol transport since its depletion resulted in accumulation of cholesterol in lysosomes, a phenotype associated with lysosomal storage disorders [14]. The trafficking defect was a consequence of decreased membrane contacts between the lysosomes and peroxisomes due to altered PI-4,5-P<sub>2</sub> homeostasis on peroxisome membranes [68] (Fig. 3). In this study, cholesterol trafficking did not seem to depend on the beta or the gamma isoforms. Evidence in support of targeting cholesterol trafficking for inhibition of tumor progression has been shown by a study with an approved drug, Cepharanthine, which inhibited endolysosomal trafficking of free-cholesterol and suppressed tumor growth [69], raising the possibility of a similar outcome with PI5P4K $\alpha$  inhibitors.

The role of PI5P4Ks in inter organelle communication has been expanded to include peroxisomes and mitochondria, both of which are very intimately connected. Dysregulated organelle communication has pathological implications, including cancer. Mitochondria are the most metabolically active organelles and a critical hub for cellular energy requirements and are therefore vital in sustaining the growth and survival of cancer cells [70]. Therefore, targeting mitochondrial metabolism is an attractive concept to suppress cancers that have been characterized as having profound metabolic alterations and have limited treatment options, such as TNBC [71] and soft tissue SARCs [72]. Interestingly, alterations in peroxisomal PI-4,5-P<sub>2</sub> due to loss of both  $\alpha$  and  $\beta$  isoforms impairs trafficking of very long chain fatty acids to peroxisomes leading to mitochondrial defects that are manifested as decreased mitochondrial membrane potential and disrupted structural integrity [37] (Fig. 3). These PI5P4K-depleted cells are able to maintain viability under normal conditions, but collapse when placed under nutrient stress, a situation commonly faced by cancer cells, indicating that the kinases play an integral role in metabolic addictions of cancer cells, presenting them as a promising candidate for therapeutic targeting in TNBC and SARCs.

Besides being stress sensors, PI5P4Ks, specifically the  $\beta$  isoform, were also shown to be a sensor of cellular GTP due to its ability to preferentially utilize GTP over ATP to generate PI-4,5-P<sub>2</sub> from PI-5-P. This GTP sensing ability was further elucidated to be important for tumorigenesis since expression of GTP-

insensitive mutant *Pip4k2b* in SV40 T-antigen immortalized MEFs resulted in the absence of tumor growth in nude mice [61]. This suggested that changes in GTP concentration can be sensed by PI5P4K $\beta$  and are transduced to PI-5-P signaling, allowing for metabolic adaptations and cancer growth, making this feature an important consideration when developing inhibitors of the  $\beta$  isoform.

Lastly, a minimally explored dimension of PI5P4Ks function is whether its catalytic activity is the sole executor of its *in vivo* roles. PI5P4K $\alpha$ -mediated degradation of the PI3K complex subunits in the GBM model is independent of the kinase activity [53]. Another couple of recent studies also suggested a non-catalytic function in the regulation of insulin signaling and PI-3,4,5-P<sub>3</sub> turnover [56,73]. These findings certainly warrant further investigation as many kinases are found to have such moonlighting functions.

Summarizing the metabolic roles of PI5P4Ks, it can be concluded that these enzymes become conditionally essential during energy stress and can regulate various nodes of metabolism. The mechanisms by which PI5P4Ks play a role in these dependencies are just beginning to be understood, and a deeper knowledge of how PI5P4Ks govern the metabolic networks will allow stratification of patients into metabolic profiles that would benefit the most from drugs targeting PI5P4Ks.

### Immune modulation

Tumor microenvironment modulation involves evasive maneuvers by cancer cells to avoid assault from the host immune response. Given the exploding research into the immune microenvironment in cancer, it is exciting to see evidence for PI5P4Ks in immune modulation. As mentioned above, mice lacking PI5P4K $\gamma$  have increased inflammation characterized by decreased regulatory effector cells [17]. Highlighting PI5P4Ks role in T-cell signaling, a recent study demonstrated that PI5P4Ks are expressed in both T effector as well as in T<sub>regs</sub>, but their inhibition restricted the functions of only the T<sub>regs</sub> but not the T effector cells, which target the cancer cells [62] (Fig. 3). This study implicated the  $\beta$  and  $\gamma$  isoforms in the transcriptional reprogramming of the T<sub>regs</sub> through alteration in PI3K signaling and consequent changes in the expression of FOXP3, which is the T<sub>regs</sub> master regulator. Infiltration of tumors with the T<sub>regs</sub> is often associated with poor prognosis [74] and thus, targeting PI5P4Ks could allow for improved immunotherapy treatment through preferential inhibition of the immunosuppressive T<sub>reg</sub> cell population.

### Targeting PI5P4Ks with small molecule inhibitors

With the expanding implications of the PI5P4Ks in multiple cancers and a better understanding of the functional biology of this family of lipid kinases, it is not surprising that there is an increasing focus toward therapeutic exploitation of these enzymes. Given the current roles of the PI5P4Ks in cancer cell-intrinsic metabolism as well as in immune response, it is motivating to surmise that PI5P4K inhibitors will exercise a multipronged impact on tumor control, allowing for better handling of pharmacological challenges arising due to tumor heterogeneity (Fig. 3).

In fact, efforts have been made to identify and characterize pan inhibitors [33,34] as well as isoform specific inhibitors of PI5P4Ks [75,76], and over the years, there have been reports of more potent and selective small molecule inhibitors [60,77–79], strengthening the evidence for efficient druggability of the PI5P4Ks. Recently in an attempt to identify drugs that are selectively lethal to cancer cells but not to normal cells, a novel compound, a131, was identified and interestingly, the group discovered that the target of the a131 compound is indeed the PI5P4Ks and it selectively regulated the cell cycle entry of Ras-activated cancer cells resulting in their death through mitotic catastrophe, while causing reversible growth arrest in normal cells [77]. This study provides further support for the critical role of PI5P4Ks in cancer cell dependencies. Later, PI5P4K $\alpha$  was also identified in a genome-wide RNAi screen using a colorectal cancer cell line to identify synthetic lethal interactions with KRAS, further supporting its interaction with activated Ras signaling [80]. Another recently identified inhibitor is a pan-PI5P4K inhibitor, THZ-P1–2, which covalently modifies the cysteines in a loop close to the ATP-binding kinase domain of all the three isoforms. Treatment with THZ-P1–2 successfully phenocopied the impairment of autophagy flux as seen with genetic ablation of the kinases and also resulted in increased survival sensitivity in six AML/ALL cell lines. With regard to off-target effects, the inhibitor exerted a potent effect on PIKfyve, and also on BRK and ABL1, underscoring the need for further improvement [79]. In a follow-up study by the same group, they sought to find reversible inhibitors of PI5P4Ks so that issues associated with acquired resistance of tumor cells could be avoided. Among a library of approximately 6000 kinase inhibitors, they identified a potent inhibitor and further developed a pan-PI5P4K inhibitor with better selectivity [78]. Most recently, a noncovalent dual PI5P4K $\alpha/\beta$  inhibitor, CC260, was identified using a high-throughput screen among 5759 small molecules. CC260 treatment was shown to affect

AKT phosphorylation and impair cellular energetics as demonstrated by changes in AMPK activation, mTOR inhibition, and decreased mitochondrial ATP production [60]. CC260 treatment increased the sensitivity of cancer cells to nutrient stress and was also able to selectively kill p53 mutant breast cancer cells [60], confirming several published data from our laboratory and others. Even though the CC260 compound appears to engage with the intended target, it does have significant off-target activity against PI3K- $\delta$ , indicating that there is still enough scope to improve the specificity and overall pharmacokinetics of the inhibitor. Nonetheless, this study strengthens the role of PI5P4Ks in cellular energetics (Fig. 3), and given the role of p53 in cellular energy metabolism, it is most likely that dual loss of the kinase and p53 function creates excessive energy stress specially for the metabolically constrained tumor cells. With further improvements in specificity of the inhibitors, the next steps will be to test their safety, efficacy, and dosage requirements in preclinical mouse models, including the *Trp53*<sup>-/-</sup> GEM model, following which it would be more apparent if these inhibitors could be beneficial on their own or would require a combinatorial approach. Further, it remains to be tested if PI5P4K $\alpha/\beta$  inhibitors could also be used to exploit the vulnerabilities created by the frequently occurring p53 missense mutations in human cancers. It is promising though that the inhibitor candidates thus far, especially the dual CC260 PI5P4K $\alpha/\beta$  inhibitor, can phenocopy the some of the effects seen with targeting PI5P4Ks using genetic tools and cancer models. Additionally, it is also important to consider the fact that the kinases can exert non catalytic activity, and if such a role is crucial for tumorigenesis, then a PROTAC (Proteolysis targeting chimeras)-based strategy [81] to degrade the entire protein could be effective and thus should be taken into consideration for developing targeting approaches for PI5P4Ks.

In the end, to date most of the cellular and *in vivo* evidence points toward oncogenic roles of PI5P4Ks and thus fuels the need for inhibitors. It is possible that in the near future there might be more indications for a tumor suppressor role of PI5P4Ks as seen in the GBM study and that would indicate that these enzymes are regulated differently depending on metabolic or tumor microenvironment cues with the ultimate objective to benefit tumor cells.

## Conclusion and perspective

From a therapeutic perspective, it is evident that pharmacological manipulation of PI5P4Ks will have beneficial effects for cancer patients, but, clearly, there is a requirement for experimental studies on different

cancer subtypes to identify the genetic and metabolic contexts under which cancer cells will be most vulnerable to PI5P4K inhibitors. Further in this context, there is a need for more high-throughput analyses of patient data in multiple cancers to get an overview of association between distribution and expression of the PI5P4K isoforms with stages and subtypes to successfully foresee the patient pool who would be most responsive to PI5P4K targeted therapy. Also, it will be crucial to identify the specific isoforms that cancer subtypes are dependent on for tumor growth. Currently, what we can infer from published work is that p53-deficient cancers, especially breast tumors, and high-grade soft tissue SARCAs will require dual inhibitors that target both PI5P4K isoforms,  $\alpha$  and  $\beta$ , whereas AML seems to require inhibition of the  $\alpha$  isoform only.

Further functional understanding of the PI5P4Ks in oncogenic dependencies requires additional investigation into the regulation of their cellular distribution and kinase activity, identification of downstream effectors, and interaction partners and finally the function(s) of their substrate PI-5-P and product PI-4,5-P<sub>2</sub> in the pathogenesis of cancer. It will be crucial to assess whether it is PI5P4K's role in suppressing PI-5-P, or its ability to generate specialized local pools of PI-4,5-P<sub>2</sub> at subcellular compartments or both, that is required in the context of tumorigenesis. With advancements in lipidomics and improved imaging techniques, and abilities to visualize the phosphoinositide pools *in vivo* as well as the distribution of endogenous kinases, we might have better insights into how cells respond to variations in these pools [82]. Nonetheless, with the emerging evidence of PI5P4Ks in cancer, it is important to leverage our current knowledge to assess PI5P4K inhibitors in cancer models so as to allow for a quicker bench-to-bedside transition.

## Author contributions

GKA and BME wrote the review. LP designed the artwork for the figures and tables.

## References

- 1 Hammond GRV, Burke JE. Novel roles of phosphoinositides in signaling, lipid transport, and disease. *Curr Opin Cell Biol.* 2020;63:57–67.
- 2 Thapa N, Tan X, Choi S, Lambert PF, Rapraeger AC, Anderson RA. The hidden conundrum of phosphoinositide signaling in cancer. *Trends Cancer.* 2016;2:378–90.

- 3 Pendaries C, Tronchere H, Plantavid M, Payastre B. Phosphoinositide signaling disorders in human diseases. *FEBS Lett.* 2003;**546**:25–31.
- 4 Balla T. Phosphoinositides: tiny lipids with giant impact on cell regulation. *Physiol Rev.* 2013;**93**:1019–137.
- 5 Beziau A, Brand D, Piver E. The role of phosphatidylinositol phosphate kinases during viral infection. *Viruses.* 2020;**12**.
- 6 Vanhaesebroeck B, Perry MWD, Brown JR, Andre F, Okkenhaug K. PI3K inhibitors are finally coming of age. *Nat Rev Drug Discov.* 2021.
- 7 Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. *J Biol Chem.* 1998;**273**:13375–8.
- 8 Czech MP. PIP2 and PIP3: complex roles at the cell surface. *Cell.* 2000;**100**:603–6.
- 9 Sun Y, Thapa N, Hedman AC, Anderson RA. Phosphatidylinositol 4,5-bisphosphate: targeted production and signaling. *BioEssays.* 2013;**35**:513–22.
- 10 Bazenet CE, Ruano AR, Brockman JL, Anderson RA. The human erythrocyte contains two forms of phosphatidylinositol-4-phosphate 5-kinase which are differentially active toward membranes. *J Biol Chem.* 1990;**265**:18012–22.
- 11 Ling LE, Schulz JT, Cantley LC. Characterization and purification of membrane-associated phosphatidylinositol-4-phosphate kinase from human red blood cells. *J Biol Chem.* 1989;**264**:5080–8.
- 12 Rameh LE, Tolia K, Duckworth BC, Cantley LC. A new pathway for synthesis of phosphatidylinositol-4,5-bisphosphate. *Nature.* 1997;**390**:192–6.
- 13 Lundquist MR, Goncalves MD, Loughran RM, Possik E, Vijayaraghavan T, Yang A et al. Phosphatidylinositol-5-phosphate 4-kinases regulate cellular lipid metabolism by facilitating autophagy. *Mol Cell.* 2018;**70**:531–44.
- 14 Hu A, Zhao XT, Tu H, Xiao T, Fu T, Wang Y et al. PIP4K2A regulates intracellular cholesterol transport through modulating PI(4,5)P2 homeostasis. *J Lipid Res.* 2018;**59**:507–14.
- 15 Emerling BM, Hurov JB, Poulogiannis G, Tsukazawa KS, Choo-Wing R, Wulf GM et al. Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors. *Cell.* 2013;**155**:844–57.
- 16 Lamia KA, Peroni OD, Kim YB, Rameh LE, Kahn BB, Cantley LC. Increased insulin sensitivity and reduced adiposity in phosphatidylinositol 5-phosphate 4-kinase beta-/- mice. *Mol Cell Biol.* 2004;**24**:5080–7.
- 17 Shim H, Wu C, Ramsamooj S, Bosch KN, Chen Z, Emerling BM et al. Deletion of the gene *Pip4k2c*, a novel phosphatidylinositol kinase, results in hyperactivation of the immune system. *Proc Natl Acad Sci USA.* 2016;**113**:7596–601.
- 18 Clarke JH, Irvine RF. Evolutionarily conserved structural changes in phosphatidylinositol 5-phosphate 4-kinase (PI5P4K) isoforms are responsible for differences in enzyme activity and localization. *Biochem J.* 2013;**454**:49–57.
- 19 Lecompte O, Poch O, Laporte J. PtdIns5P regulation through evolution: roles in membrane trafficking? *Trends Biochem Sci.* 2008;**33**:453–60.
- 20 Gupta A, Toscano S, Trivedi D, Jones DR, Mathre S, Clarke JH et al. Phosphatidylinositol 5-phosphate 4-kinase (PIP4K) regulates TOR signaling and cell growth during *Drosophila* development. *Proc Natl Acad Sci USA.* 2013;**110**:5963–8.
- 21 Clarke JH, Irvine RF. The activity, evolution and association of phosphatidylinositol 5-phosphate 4-kinases. *Adv Biol Regul.* 2012;**52**:40–5.
- 22 Burke JE. Structural basis for regulation of phosphoinositide kinases and their involvement in human disease. *Mol Cell.* 2018;**71**:653–73.
- 23 Muftuoglu Y, Xue Y, Gao X, Wu D, Ha Y. Mechanism of substrate specificity of phosphatidylinositol phosphate kinases. *Proc Natl Acad Sci USA.* 2016;**113**:8711–6.
- 24 Clarke JH, Wang M, Irvine RF. Localization, regulation and function of type II phosphatidylinositol 5-phosphate 4-kinases. *Adv Enzyme Regul.* 2010;**50**:12–8.
- 25 Wang M, Bond NJ, Letcher AJ, Richardson JP, Lilley KS, Irvine RF et al. Genomic tagging reveals a random association of endogenous PtdIns5P 4-kinases IIalpha and IIbeta and a partial nuclear localization of the IIalpha isoform. *Biochem J.* 2010;**430**:215–21.
- 26 Bultsma Y, Keune WJ, Divecha N. PIP4Kbeta interacts with and modulates nuclear localization of the high-activity PtdIns5P-4-kinase isoform PIP4Kalpha. *Biochem J.* 2010;**430**:223–35.
- 27 Fiume R, Stijf-Bultsma Y, Shah ZH, Keune WJ, Jones DR, Jude JG et al. PIP4K and the role of nuclear phosphoinositides in tumour suppression. *Biochim Biophys Acta.* 2015;**1851**:898–910.
- 28 Vicinanza M, Korolchuk VI, Ashkenazi A, Puri C, Menzies FM, Clarke JH et al. PI(5)P regulates autophagosome biogenesis. *Mol Cell.* 2015;**57**:219–34.
- 29 Clarke JH, Emson PC, Irvine RF. Localization of phosphatidylinositol phosphate kinase IIgamma in kidney to a membrane trafficking compartment within specialized cells of the nephron. *Am J Physiol Renal Physiol.* 2008;**295**:F1422–30.
- 30 Jones DR, Bultsma Y, Keune WJ, Halstead JR, Elouarrat D, Mohammed S et al. Nuclear PtdIns5P as a transducer of stress signaling: an in vivo role for PIP4Kbeta. *Mol Cell.* 2006;**23**:685–95.
- 31 Jones DR, Foulger R, Keune WJ, Bultsma Y, Divecha N. PtdIns5P is an oxidative stress-induced second messenger that regulates PKB activation. *FASEB J.* 2013;**27**:1644–56.

- 32 Keune WJ, Jones DR, Divecha N. PtdIns5P and Pin1 in oxidative stress signaling. *Adv Biol Regul.* 2013;**53**:179–89.
- 33 Keune WJ, Jones DR, Bultsma Y, Sommer L, Zhou XZ, Lu KP et al. Regulation of phosphatidylinositol-5-phosphate signaling by Pin1 determines sensitivity to oxidative stress. *Sci Signal.* 2012;**5**:ra86.
- 34 Chen Y, Wu YR, Yang HY, Li XZ, Jie MM, Hu CJ et al. Prolyl isomerase Pin1: a promoter of cancer and a target for therapy. *Cell Death Dis.* 2018;**9**:883.
- 35 Mackey AM, Sarkes DA, Bettencourt I, Asara JM, Rameh LE. PIP4kgamma is a substrate for mTORC1 that maintains basal mTORC1 signaling during starvation. *Sci Signal.* 2014;**7**:ra104.
- 36 Wilcox A, Hinchliffe KA. Regulation of extranuclear PtdIns5P production by phosphatidylinositol phosphate 4-kinase 2alpha. *FEBS Lett.* 2008;**582**:1391–4.
- 37 Ravi A, Palamiuc L, Loughran RM, Triscott J, Arora GK, Kumar A et al. PI5P4Ks drive metabolic homeostasis through peroxisome-mitochondria interplay. *Dev Cell.* 2021;**56**:1661–76.
- 38 Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Res.* 2017;**45**:W98–W102.
- 39 Luoh SW, Venkatesan N, Tripathi R. Overexpression of the amplified Pip4k2beta gene from 17q11-12 in breast cancer cells confers proliferation advantage. *Oncogene.* 2004;**23**:1354–63.
- 40 Keune WJ, Sims AH, Jones DR, Bultsma Y, Lynch JT, Jirstrom K et al. Low PIP4K2B expression in human breast tumors correlates with reduced patient survival: A role for PIP4K2B in the regulation of E-cadherin expression. *Cancer Res.* 2013;**73**:6913–25.
- 41 Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. *Science.* 2017;**355**:1152–8.
- 42 Terkelsen T, Pernemalm M, Gromov P, Borresen-Dale AL, Krogh A, Haakensen VD et al. High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers. *Mol Oncol.* 2021;**15**:429–61.
- 43 Lima K, Coelho-Silva JL, Kinker GS, Pereira-Martins DA, Traina F, Fernandes P et al. PIP4K2A and PIP4K2C transcript levels are associated with cytogenetic risk and survival outcomes in acute myeloid leukemia. *Cancer Genet.* 2019;**233–234**:56–66.
- 44 Lima K, Ribeiro DM, Campos Pde M, Costa FF, Traina F, Saad ST et al. Differential profile of PIP4K2A expression in hematological malignancies. *Blood Cells Mol Dis.* 2015;**55**:228–35.
- 45 Ratti S, Evangelisti C, Mongiorgi S, De Stefano A, Fazio A, Bonomini F et al. Modulating phosphoinositide profiles as a roadmap for treatment in acute myeloid leukemia. *Front Oncol.* 2021;**11**:678824.
- 46 Jabbour E, Ottmann OG, Deininger M, Hochhaus A. Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. *Haematologica.* 2014;**99**:7–18.
- 47 Jude JG, Spencer GJ, Huang X, Somerville TDD, Jones DR, Divecha N et al. A targeted knockdown screen of genes coding for phosphoinositide modulators identifies PIP4K2A as required for acute myeloid leukemia cell proliferation and survival. *Oncogene.* 2015;**34**:1253–62.
- 48 Xu H, Yang W, Perez-Andreu V, Devidas M, Fan Y, Cheng C et al. Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. *J Natl Cancer Inst.* 2013;**105**:733–42.
- 49 Zhang S, Li Z, Yan X, Bao L, Deng Y, Zeng F et al. Regulatory network and prognostic effect investigation of PIP4K2A in leukemia and solid cancers. *Front Genet.* 2018;**9**:721.
- 50 Migliorini G, Fiege B, Hosking FJ, Ma Y, Kumar R, Sherborne AL et al. Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype. *Blood.* 2013;**122**:3298–307.
- 51 Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. *Neuro Oncol.* 2017;**19**:v1–v88.
- 52 Eckerdt FD, Bell JB, Gonzalez C, Oh MS, Perez RE, Mazewski C et al. Combined PI3Kalpha-mTOR targeting of glioma stem cells. *Sci Rep.* 2020;**10**:21873.
- 53 Shin YJ, Sa JK, Lee Y, Kim D, Chang N, Cho HJ et al. PIP4K2A as a negative regulator of PI3K in PTEN-deficient glioblastoma. *J Exp Med.* 2019;**216**:1120–34.
- 54 Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine. *CA Cancer J Clin.* 2020;**70**:200–29.
- 55 Kirsch DG, Dinulescu DM, Miller JB, Grimm J, Santiago PM, Young NP et al. A spatially and temporally restricted mouse model of soft tissue sarcoma. *Nat Med.* 2007;**13**:992–7.
- 56 Sharma S, Mathre S, Ramya V, Shinde D, Raghu P. Phosphatidylinositol 5 phosphate 4-kinase regulates plasma-membrane PIP3 turnover and insulin signaling. *Cell Rep.* 2019;**27**:1979–90.
- 57 Viaud J, Lagarrigue F, Ramel D, Allart S, Chicanne G, Ceccato L et al. Phosphatidylinositol 5-phosphate regulates invasion through binding and activation of Tiam1. *Nat Commun.* 2014;**5**:4080.
- 58 Oppelt A, Lobert VH, Haglund K, Mackey AM, Rameh LE, Liestol K et al. Production of phosphatidylinositol 5-phosphate via PIKfyve and



- MTMR3 regulates cell migration. *EMBO Rep.* 2013;**14**:57–64.
- 59 Elouarrat D, van der Velden YU, Jones DR, Moolenaar WH, Divecha N, Haramis AP. Role of phosphatidylinositol 5-phosphate 4-kinase alpha in zebrafish development. *Int J Biochem Cell Biol.* 2013;**45**:1293–301.
  - 60 Chen S, Chandra Tjin C, Gao X, Xue Y, Jiao H, Zhang R et al. Pharmacological inhibition of PI5P4Kalpha/beta disrupts cell energy metabolism and selectively kills p53-null tumor cells. *Proc Natl Acad Sci USA.* 2021;**118**:2002486118.
  - 61 Sumita K, Lo YH, Takeuchi K, Senda M, Kofuji S, Ikeda Y et al. The Lipid Kinase PI5P4Kbeta Is an Intracellular GTP Sensor for Metabolism and Tumorigenesis. *Mol Cell.* 2016;**61**:187–98.
  - 62 Poli A, Abdul-Hamid S, Zaurito AE, Campagnoli F, Bevilacqua V, Sheth B et al. PIP4Ks impact on PI3K, FOXP3, and UHRF1 signaling and modulate human regulatory T cell proliferation and immunosuppressive activity. *Proc Natl Acad Sci.* 2021;**118**:e2010053118.
  - 63 Bulley SJ, Clarke JH, Droubi A, Giudici ML, Irvine RF. Exploring phosphatidylinositol 5-phosphate 4-kinase function. *Adv Biol Regul.* 2015;**57**:193–202.
  - 64 Sasaki T, Takasuga S, Sasaki J, Kofuji S, Eguchi S, Yamazaki M et al. Mammalian phosphoinositide kinases and phosphatases. *Prog Lipid Res.* 2009;**48**:307–43.
  - 65 Mulcahy Levy JM, Thorburn A. Autophagy in cancer: moving from understanding mechanism to improving therapy responses in patients. *Cell Death Differ.* 2020;**27**:843–57.
  - 66 Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. *Nat Rev Cancer.* 2017;**17**:528–42.
  - 67 Huang B, Song BL, Xu C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. *Nat Metab.* 2020;**2**:132–41.
  - 68 Chu BB, Liao YC, Qi W, Xie C, Du X, Wang J et al. Cholesterol transport through lysosome-peroxisome membrane contacts. *Cell.* 2015;**161**:291–306.
  - 69 Lyu J, Yang EJ, Head SA, Ai N, Zhang B, Wu C et al. Pharmacological blockade of cholesterol trafficking by cepharanthine in endothelial cells suppresses angiogenesis and tumor growth. *Cancer Lett.* 2017;**409**:91–103.
  - 70 Wallace DC. Mitochondria and cancer. *Nat Rev Cancer.* 2012;**12**:685–98.
  - 71 Mehanna J, Haddad FG, Eid R, Lambertini M, Kourie HR. Triple-negative breast cancer: current perspective on the evolving therapeutic landscape. *Int J Womens Health.* 2019;**11**:431–7.
  - 72 Huangyang P, Li F, Lee P, Nissim I, Weljie AM, Mancuso A et al. Fructose-1,6-bisphosphatase 2 inhibits sarcoma progression by restraining mitochondrial biogenesis. *Cell Metab.* 2020;**31**:1032.
  - 73 Wang DG, Paddock MN, Lundquist MR, Sun JY, Mashadova O, Amadiume S et al. PIP4Ks suppress insulin signaling through a catalytic-independent mechanism. *Cell Rep.* 2019;**27**:1991–2001.
  - 74 Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. *Cell Res.* 2017;**27**:109–18.
  - 75 Voss MD, Czechizky W, Li Z, Rudolph C, Petry S, Brummerhop H et al. Discovery and pharmacological characterization of a novel small molecule inhibitor of phosphatidylinositol-5-phosphate 4-kinase, type II, beta. *Biochem Biophys Res Commun.* 2014;**449**:327–31.
  - 76 Davis MI, Sasaki AT, Shen M, Emerling BM, Thorne N, Michael S et al. A homogeneous, high-throughput assay for phosphatidylinositol 5-phosphate 4-kinase with a novel, rapid substrate preparation. *PLoS One.* 2013;**8**:e54127.
  - 77 Kitagawa M, Liao PJ, Lee KH, Wong J, Shang SC, Minami N et al. Dual blockade of the lipid kinase PIP4Ks and mitotic pathways leads to cancer-selective lethality. *Nat Commun.* 2017;**8**:2200.
  - 78 Manz TD, Sivakumaren SC, Ferguson FM, Zhang T, Yasgar A, Seo HS et al. Discovery and structure-activity relationship Study of (Z)-5-methylenethiazolidin-4-one derivatives as potent and selective pan-phosphatidylinositol 5-phosphate 4-kinase inhibitors. *J Med Chem.* 2020;**63**:4880–95.
  - 79 Sivakumaren SC, Shim H, Zhang T, Ferguson FM, Lundquist MR, Browne CM et al. Targeting the PI5P4K lipid kinase family in cancer using covalent inhibitors. *Cell Chem Biol.* 2020;**27**:525–37.
  - 80 Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. *Cell.* 2009;**137**:835–48.
  - 81 Sun X, Gao H, Yang Y, He M, Wu Y, Song Y et al. PROTACs: great opportunities for academia and industry. *Signal Transduct Target Ther.* 2019;**4**:64.
  - 82 Montano-Rendon F, Grinstein S, Walpole GFW. Monitoring phosphoinositide fluxes and effectors during leukocyte chemotaxis and phagocytosis. *Front Cell Dev Biol.* 2021;**9**:626136.